iZafe Group AB has signed a letter of intent to acquire 100 per cent of the shares in Pilloxa.
Pilloxa has developed a technology platform that improves patient engagement and compliance.
The acquisition is set to create a new digital health company that is well positioned to become a leading player in better, safer drug use.
Medication errors are a significant and costly problem for individuals and drug development companies alike.
Supporting patients to take their medication correctly is an effective way to achieve better medical outcomes.
Both iZafe and Pilloxa offer solutions in this area. The merger will deliver a broader offering to healthcare providers, the pharmaceutical industry and consumers.
It also broadens the customer base and is expected to accelerate market penetration.
Helena Rönnqvist, CEO at Pilloxa, said:
“With Pilloxa’s digital offering and long-term collaboration with the pharmaceutical industry, together with iZafe, we can offer a comprehensive solution for our customers; patients, healthcare professionals and the pharmaceutical industry.
“Pilloxa’s promise to our customers today is a complete digital solution for patient support within one month of the initiation meeting.
“We are therefore used to rapid integrations and will immediately begin work on offering a joint digital solution.”
Swedish company Pilloxa works to develop apps for patients to support them in adherence to their treatment and to connect patients, healthcare providers and the pharmaceutical industry.
The company provides a SaaS platform where pharmaceutical companies and other customers can design digital patient support quickly, securely and at a low cost.
Pilloxa’s self-developed smart medication dose and other connected aids can also be connected to the service to support patients in taking the correct medication.
Customers and partners include Bayer Nordics, the Nordic office of Chiesi Global Rare Diseases, university hospitals such as the University Hospital in Oslo and universities such as the University of Gothenburg.
